ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

PDLI PDL BioPharma Inc

2.47
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
PDL BioPharma Inc NASDAQ:PDLI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.47 2.62 2.63 0 01:00:00

PDL BioPharma to Present at the 2017 RBC Capital Markets Global Healthcare Conference

17/02/2017 12:00pm

PR Newswire (US)


PDL BioPharma (NASDAQ:PDLI)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more PDL BioPharma Charts.

INCLINE VILLAGE, Nev., Feb. 17, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will participate in a fireside chat at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York. The session will be webcast live and will occur on Wednesday February 22, 2017 at 2:35 p.m. EST.

To access the live and subsequently archived webcast of the presentation, go to the company's website at http://www.pdl.com and go to "Presentations and Events." Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The archived webcast will be available for at least seven days following the presentation.

About PDL BioPharma
PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries.  In late 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities and in 2016, began making equity investments in commercial stage companies, the first being Noden Pharma DAC.  PDL has committed over $1.4 billion and funded approximately $1.1 billion in these investments to date.

PDL was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.  PDL was founded in 1986 and is headquartered in Incline Village, Nevada.  PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it has received significant royalty revenue.

NOTE:  PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conference-300409359.html

SOURCE PDL BioPharma, Inc.

Copyright 2017 PR Newswire

1 Year PDL BioPharma Chart

1 Year PDL BioPharma Chart

1 Month PDL BioPharma Chart

1 Month PDL BioPharma Chart

Your Recent History

Delayed Upgrade Clock